Nature Communications (Aug 2021)

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment

  • Hua Sun,
  • Song Cao,
  • R. Jay Mashl,
  • Chia-Kuei Mo,
  • Simone Zaccaria,
  • Michael C. Wendl,
  • Sherri R. Davies,
  • Matthew H. Bailey,
  • Tina M. Primeau,
  • Jeremy Hoog,
  • Jacqueline L. Mudd,
  • Dennis A. Dean,
  • Rajesh Patidar,
  • Li Chen,
  • Matthew A. Wyczalkowski,
  • Reyka G. Jayasinghe,
  • Fernanda Martins Rodrigues,
  • Nadezhda V. Terekhanova,
  • Yize Li,
  • Kian-Huat Lim,
  • Andrea Wang-Gillam,
  • Brian A. Van Tine,
  • Cynthia X. Ma,
  • Rebecca Aft,
  • Katherine C. Fuh,
  • Julie K. Schwarz,
  • Jose P. Zevallos,
  • Sidharth V. Puram,
  • John F. Dipersio,
  • The NCI PDXNet Consortium,
  • Brandi Davis-Dusenbery,
  • Matthew J. Ellis,
  • Michael T. Lewis,
  • Michael A. Davies,
  • Meenhard Herlyn,
  • Bingliang Fang,
  • Jack A. Roth,
  • Alana L. Welm,
  • Bryan E. Welm,
  • Funda Meric-Bernstam,
  • Feng Chen,
  • Ryan C. Fields,
  • Shunqiang Li,
  • Ramaswamy Govindan,
  • James H. Doroshow,
  • Jeffrey A. Moscow,
  • Yvonne A. Evrard,
  • Jeffrey H. Chuang,
  • Benjamin J. Raphael,
  • Li Ding

DOI
https://doi.org/10.1038/s41467-021-25177-3
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 20

Abstract

Read online

Patient-derived xenograft models (PDX) have been extensively used to study the molecular and clinical features of cancers. Here the authors present a cohort of 536 PDX models from 25 cancers, as well as their genomic and evolutionary profiles and their suitability for clinical trials.